Terms: = Lymphoma AND SETD2, ENSG00000181555, 29072 AND Treatment
14 results:
1. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract] [Full Text] [Related]
2. Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma.
Kwok HS; Freedy AM; Siegenfeld AP; Morriss JW; Waterbury AL; Kissler SM; Liau BB
Nat Chem Biol; 2023 Sep; 19(9):1105-1115. PubMed ID: 36973442
[TBL] [Abstract] [Full Text] [Related]
3. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
[TBL] [Abstract] [Full Text] [Related]
4. Comparative Molecular Analysis of Primary Central Nervous System lymphomas and Matched Vitreoretinal lymphomas by Vitreous Liquid Biopsy.
Balikov DA; Hu K; Liu CJ; Betz BL; Chinnaiyan AM; Devisetty LV; Venneti S; Tomlins SA; Cani AK; Rao RC
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576156
[TBL] [Abstract] [Full Text] [Related]
5. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.
Zhou B; Chu X; Tian H; Liu T; Liu H; Gao W; Chen S; Hu S; Wu D; Xu Y
Am J Hematol; 2021 Nov; 96(11):1461-1471. PubMed ID: 34406703
[TBL] [Abstract] [Full Text] [Related]
6. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
Cai MC; Cheng S; Wang X; Hu JD; Song YP; Huang YH; Yan ZX; Jiang YJ; Fang XS; Zheng XY; Dong LH; Ji MM; Wang L; Xu PP; Zhao WL
Genome Med; 2020 Apr; 12(1):41. PubMed ID: 32349779
[TBL] [Abstract] [Full Text] [Related]
7. Novel molecular targets for the treatment of lung cancer.
Rosell R; Karachaliou N; Arrieta O
Curr Opin Oncol; 2020 Jan; 32(1):37-43. PubMed ID: 31599770
[TBL] [Abstract] [Full Text] [Related]
8. Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).
Galanina N; Kurzrock R
Cancer Biol Ther; 2019; 20(3):247-251. PubMed ID: 30307363
[TBL] [Abstract] [Full Text] [Related]
9. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract] [Full Text] [Related]
10. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract] [Full Text] [Related]
11. The Genetic Basis of Hepatosplenic T-cell lymphoma.
McKinney M; Moffitt AB; Gaulard P; Travert M; De Leval L; Nicolae A; Raffeld M; Jaffe ES; Pittaluga S; Xi L; Heavican T; Iqbal J; Belhadj K; Delfau-Larue MH; Fataccioli V; Czader MB; Lossos IS; Chapman-Fredricks JR; Richards KL; Fedoriw Y; Ondrejka SL; Hsi ED; Low L; Weisenburger D; Chan WC; Mehta-Shah N; Horwitz S; Bernal-Mizrachi L; Flowers CR; Beaven AW; Parihar M; Baseggio L; Parrens M; Moreau A; Sujobert P; Pilichowska M; Evens AM; Chadburn A; Au-Yeung RK; Srivastava G; Choi WW; Goodlad JR; Aurer I; Basic-Kinda S; Gascoyne RD; Davis NS; Li G; Zhang J; Rajagopalan D; Reddy A; Love C; Levy S; Zhuang Y; Datta J; Dunson DB; Davé SS
Cancer Discov; 2017 Apr; 7(4):369-379. PubMed ID: 28122867
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.
Griffith M; Griffith OL; Krysiak K; Skidmore ZL; Christopher MJ; Klco JM; Ramu A; Lamprecht TL; Wagner AH; Campbell KM; Lesurf R; Hundal J; Zhang J; Spies NC; Ainscough BJ; Larson DE; Heath SE; Fronick C; O'Laughlin S; Fulton RS; Magrini V; McGrath S; Smith SM; Miller CA; Maher CA; Payton JE; Walker JR; Eldred JM; Walter MJ; Link DC; Graubert TA; Westervelt P; Kulkarni S; DiPersio JF; Mardis ER; Wilson RK; Ley TJ
Exp Hematol; 2016 Jul; 44(7):603-13. PubMed ID: 27181063
[TBL] [Abstract] [Full Text] [Related]
13. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
Xiao H; Wang LM; Luo Y; Lai X; Li C; Shi J; Tan Y; Fu S; Wang Y; Zhu N; He J; Zheng W; Yu X; Cai Z; Huang H
Oncotarget; 2016 Jan; 7(3):2696-708. PubMed ID: 26527318
[TBL] [Abstract] [Full Text] [Related]
14. Mutations in epigenetic regulators including setd2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
Mar BG; Bullinger LB; McLean KM; Grauman PV; Harris MH; Stevenson K; Neuberg DS; Sinha AU; Sallan SE; Silverman LB; Kung AL; Lo Nigro L; Ebert BL; Armstrong SA
Nat Commun; 2014 Mar; 5():3469. PubMed ID: 24662245
[TBL] [Abstract] [Full Text] [Related]
